Item 8.01 Other Events.

On July 21, 2021, KemPharm, Inc., a Delaware corporation (the "Company"), issued a press release (the "Press Release") announcing that the U.S. commercial launch of AZSTARYS™, a once-daily product for the treatment of attention deficit hyperactivity disorder ("ADHD") in patients age six years and older. Corium, Inc., a portfolio company of Gurnet Point Capital, is leading the commercialization of AZSTARYS in the U.S. The Press Release is filed, here within, as Exhibit 99.1 to this Current Report on Form 8-K.




Item 9.01      Financial Statements and Exhibits.



(d) Exhibits




Exhibit No.                                Description
   99.1         Press Release titled "KemPharm Announces U.S. Launch of Innovative
              ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate
              capsules) by Corium, Inc." dated July 21, 2021.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses